
  
    
      
        Background_NNP
        Proliferation_NNP and_CC dedifferentiation_NN of_IN HIV-_NNP 1_CD infected_JJ
        renal_JJ epithelium_NN is_VBZ singularly_RB unique_JJ compared_VBN to_TO the_DT
        effects_NNS of_IN HIV-_NNP 1_CD infection_NN in_IN other_JJ non-lymphoid_JJ tissues_NNS ._.
        Indeed_RB ,_, unlike_IN the_DT atrophy_NN and_CC cell-death_JJ of_IN infected_JJ
        central_JJ nervous_JJ system_NN [_NN 1_CD ]_NN ,_, cardiac_JJ [_NN 2_CD ]_NN ,_, or_CC
        gastro-intestinal_JJ [_NN 3_CD ]_NN parenchyma_NN ,_, aberrant_NN cell-cycle_JJ
        progression_NN of_IN infected_JJ renal_JJ epithelium_NN is_VBZ a_DT defining_VBG
        feature_NN of_IN HIV-associated_NNP nephropathy_NN (_( HIVAN_NNP )_) [_NN 4_CD 5_CD ]_NN ._.
        Yet_RB ,_, the_DT mechanisms_NNS are_VBP largely_RB unknown_JJ whereby_WRB HIV-_NNP 1_CD
        subverts_VBZ the_DT cell-cycle_JJ controls_NNS that_WDT normally_RB maintain_VB
        renal_JJ epithelial_NN in_IN G_NNP 
        0_CD ._. Nonetheless_RB ,_, several_JJ observations_NNS
        from_IN 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN models_NNS of_IN HIVAN_NNP pathogenesis_NNS
        suggest_VBP that_IN HIV-_NNP 1_CD expression_NN itself_PRP may_MD be_VB a_DT key_JJ
        pathogenic_JJ factor_NN ._. Infection_NNP of_IN cultured_JJ podocytes_NNS with_IN
        replication_NN incompetent_JJ HIV-_NNP 1_CD demonstrated_VBN that_IN HIV-_NNP 1_CD gene_NN
        expression_NN leads_VBZ to_TO the_DT proliferation_NN and_CC dedifferentiation_NN
        of_IN the_DT infected_JJ podocytes_NNS [_NN 6_CD 7_CD 8_CD ]_NN ,_, recapitulating_VBG the_DT
        phenotypes_NNS observed_VBD in_IN HIVAN_NNP specimens_NNS [_NN 9_CD 10_CD ]_NN ._.
        Similarly_RB ,_, renal_JJ expression_NN of_IN replication_NN incompetent_JJ
        HIV-_NNP 1_CD proviral_NN transgenes_NNS in_IN mice_NNS and_CC rats_NNS produces_VBZ a_DT
        proliferative_JJ renal_JJ lesion_NN that_WDT is_VBZ indistiguisable_JJ both_DT
        histopathologically_RB and_CC clinically_RB from_IN human_JJ HIVAN_NNP [_NN 11_CD 12_CD
        13_CD 14_CD ]_NN ._. These_DT observations_NNS raise_VBP the_DT possibility_NN that_IN
        HIV-_NNP 1_CD gene_NN products_NNS may_MD interact_NN with_IN mitogenic_JJ pathways_NNS in_IN
        infected_JJ renal_JJ epithelium_NN to_TO cause_VB aberrant_NN cell-cycle_JJ
        engagement_NN ._.
        In_IN comparison_NN to_TO the_DT two_CD general_JJ alternative_JJ mechanisms_NNS
        utilized_JJ by_IN known_VBN transforming_VBG viruses_NNS to_TO promote_VB
        cell-cycle_JJ progression_NN ,_, namely_RB ,_, by_IN activating_VBG or_CC bypassing_VBG
        endogenous_JJ D-_NNP type_NN cyclins_NNS (_( herein_NN ,_, referred_VBD to_TO as_IN "_'' cyclin_NN
        D_NNP "_'' )_) ,_, it_PRP has_VBZ not_RB been_VBN established_VBN whether_IN HIV-_NNP 1_CD gene_NN
        products_NNS trigger_VBP either_CC cyclin_NN D-_NNP dependent_JJ or_CC cyclin_NN
        D-_NNP independent_JJ proliferation_NN in_IN non-lymphoid_JJ tissues_NNS [_NN 15_CD ]_NN
        ._. In_IN infected_JJ renal_JJ epithelium_NN ,_, HIV-_NNP 1_CD could_MD disrupt_VB the_DT
        inhibitory_NN binding_JJ of_IN pRb_NN to_TO E_NNP 2_CD F_NN independent_JJ of_IN endogenous_JJ
        cyclin_NN D_NNP ,_, analogous_JJ to_TO transforming_VBG viral_JJ mechanisms_NNS that_WDT
        bypass_NN and_CC down-regulate_JJ endogenous_JJ cyclin_NN D_NNP ,_, such_JJ as_IN SV-_NNP 40_CD
        T_NN antigen_NN binding_JJ to_TO pRb_NN [_NN 16_CD ]_NN ,_, HHV-_NNP 8_CD 
        v_NN -_: cyclin_NN binding_JJ to_TO and_CC activating_VBG
        cyclin-dependent_JJ kinase-_NN 6_CD (_( CDK_NNP )_) [_NN 17_CD ]_NN ,_, and_CC activation_NN of_IN
        cyclin_NN E_NNP by_IN EBV-induced_NNP 
        c_SYM -_: myc_NN [_NN 18_CD ]_NN ._. Alternatively_RB ,_, HIV-_NNP 1_CD
        could_MD activate_VBP cyclin_NN D-_NNP dependent_JJ proliferation_NN ,_, as_IN
        exemplified_VBN by_IN RSV_NNP 
        v_NN -_: src-mediated_JJ signaling_VBG [_NN 19_CD ]_NN ._. In_IN
        most_JJS tissues_NNS ,_, the_DT selective_JJ activation_NN of_IN these_DT cell-cycle_JJ
        pathways_NNS is_VBZ readily_RB discernable_JJ ._. Indeed_RB ,_, if_IN cells_NNS depend_VBP on_IN
        cyclin_NN D-_NNP mediated_JJ G_NNP 1_CD →_NN S_NNP transition_NN ,_, passage_NN from_IN G_NNP 
        0_CD through_IN the_DT restriction_NN point_NN in_IN G_NNP 
        1_CD is_VBZ dependent_JJ on_IN the_DT 
        de_IN novo_NN expression_NN of_IN cyclin_NN D_NNP
        transcript_NN ,_, accumulation_NN of_IN nuclear_JJ cyclin_NN D_NNP protein_NN ,_, and_CC
        cyclin_NN D_NNP /_NN CDK-_NNP 4_CD /_NN 6_CD phosphorylation_NN of_IN pRb_NN [_NN 20_CD ]_NN ._. Then_RB ,_,
        although_IN nuclear-localized_JJ cyclin_NN D_NNP decreases_NNS in_IN S_NNP phase_NN in_IN
        individual_JJ cells_NNS [_NN 21_CD ]_NN ,_, total_JJ cyclin_NN D_NNP in_IN asynchronously_RB
        proliferating_VBG cell_NN populations_NNS remain_VBP elevated_VBD compared_VBN to_TO
        quiescent_JJ cells_NNS [_NN 20_CD ]_NN ._. In_IN renal_JJ epithelial_NN and_CC
        mesenchymal_NN cells_NNS ,_, cyclin_NN D_NNP 
        1_CD is_VBZ the_DT dominant_JJ D-_NNP type_NN cyclin_NN
        activated_VBN during_IN cell-cycle_JJ progression_NN ,_, both_DT during_IN
        nephrogenesis_NNS [_NN 22_CD ]_NN and_CC in_IN non-viral-mediated_JJ kidney_NN cell_NN
        proliferation_NN [_NN 23_CD ]_NN ._.
        Here_RB ,_, we_PRP ask_VBP whether_IN infected_JJ podocytes_NNS expressing_VBG HIV-_NNP 1_CD
        genes_NNS show_VBP the_DT hallmarks_NNS of_IN cyclin_NN D_NNP 
        1_CD -_: dependent_JJ proliferation_NN ,_, specifically_RB
        the_DT up-regulation_JJ of_IN cyclin_NN D_NNP 
        1_CD transcript_NN and_CC protein_NN expression_NN and_CC
        the_DT subsequent_JJ phosphorylation_NN of_IN pRb_NN on_IN serine_NN 780_CD ,_, a_DT
        target_NN site_NN of_IN active_JJ cyclin_NN D_NNP 
        1_CD /_NN CDK-_NNP 4_CD /_NN 6_CD that_WDT is_VBZ not_RB shared_VBN with_IN
        cyclin_NN E_NNP /_NN CDK-_NNP 2_CD complexes_NNS [_NN 24_CD ]_NN ._. Utilizing_NNP two_CD
        well-characterized_JJ models_NNS of_IN HIVAN_NNP pathogenesis_NNS ,_, HIV-_NNP 1_CD
        transgenic_JJ mice_NNS [_NN 11_CD 12_CD 13_CD ]_NN and_CC HIV-_NNP 1_CD infection_NN of_IN
        cultured_JJ podocytes_NNS [_NN 6_CD 7_CD 8_CD ]_NN we_PRP find_VBP not_RB only_RB these_DT
        hallmarks_NNS of_IN cyclin_NN D_NNP 
        1_CD -_: dependent_JJ proliferation_NN ,_, but_CC also_RB
        dysregulation_NN of_IN cyclin_NN D_NNP 
        1_CD expression_NN that_WDT normally_RB occurs_VBZ with_IN
        cell-cell_JJ contact_NN and_CC differentiation_NN [_NN 25_CD ]_NN ._.
      
      
        Results_NNS
        
          Phospho-p_NNP Rb_NNP (_( Ser_NNP 780_CD )_) expression_NN in_IN vivo_NN
          Cyclin_NNP D_NNP 
          1_CD is_VBZ characterized_VBN as_IN the_DT major_JJ D-_NNP type_NN
          cyclin_NN controlling_VBG G_NNP 
          1_CD -_: phase_NN progression_NN in_IN kidney_NN cells_NNS ,_,
          both_DT during_IN normal_JJ and_CC abnormal_JJ proliferation_NN [_NN 22_CD 23_CD ]_NN ._.
          To_TO determine_VB whether_IN cyclin_NN D_NNP 
          1_CD may_MD be_VB active_JJ in_IN promoting_VBG G_NNP 
          1_CD →_NN S_NNP progression_NN in_IN kidneys_NNS
          expressing_VBG HIV-_NNP 1_CD genes_NNS ,_, we_PRP utilized_JJ a_DT well-characterized_JJ
          HIV-_NNP 1_CD transgenic_JJ mouse_NN model_NN (_( Tg_NNP 26_CD )_) of_IN HIVAN_NNP [_NN 11_CD 12_CD 13_CD ]_NN
          ._. Secondary_JJ to_TO renal_JJ expression_NN of_IN the_DT HIV-_NNP 1_CD NL_NNP 4_CD -_: 3_CD Δ_NN 
          gag-pol_JJ proviral_NN transgene_NN ,_,
          adolescent_JJ Tg_NNP 26_CD transgenics_NNS develop_VBP a_DT progressive_JJ ,_,
          proliferative_JJ renal_JJ disease_NN marked_VBN by_IN podocyte_NN and_CC
          tubular_JJ epithelial_NN hyperplasia_NN that_WDT is_VBZ indistinguishable_JJ
          both_DT clinically_RB and_CC histopathologically_RB from_IN human_JJ HIVAN_NNP ._.
          In_IN order_NN to_TO determine_VB if_IN cyclin_NN D_NNP 
          1_CD plays_VBZ a_DT role_NN in_IN this_DT hyperplasia_NN ,_,
          kidneys_NNS from_IN three_CD proteinuric_JJ 40_CD -_: day_NN old_JJ transgenic_JJ
          siblings_NNS and_CC three_CD non-transgenic_JJ littermates_NNS were_VBD
          stained_JJ by_IN immunohistochemistry_NN with_IN antibody_NN to_TO
          phospho-p_JJ Rb_NNP (_( Ser_NNP 780_CD )_) ,_, a_DT site_NN of_IN cyclin_NN D_NNP 
          1_CD /_NN CDK-_NNP 4_CD /_NN 6_CD phosphorylation_NN not_RB
          targeted_VBN by_IN cyclin_NN E_NNP /_NN CDK-_NNP 2_CD complexes_NNS that_IN disrupts_NNS
          pRb_NN /_NN E_NNP 2_CD F_NN binding_JJ for_IN G_NNP 
          1_CD →_NN S_NNP progression_NN [_NN 24_CD ]_NN ._. Figure_NN
          1_CD depicts_VBZ the_DT intense_JJ ,_, heterogeneous_JJ nuclear_JJ staining_VBG of_IN
          glomerular_NN podocytes_NNS and_CC tubular_JJ epithelium_NN from_IN
          hyperplastic_JJ nephrons_NNS in_IN the_DT diseased_JJ transgenics_NNS versus_CC
          the_DT absent_JJ staining_VBG of_IN nephrons_NNS in_IN the_DT non-transgenics_JJ
          consistent_JJ with_IN the_DT very_RB low_JJ mitotic_JJ index_NN in_IN normal_JJ
          kidneys_NNS of_IN adult_NN animals_NNS [_NN 26_CD ]_NN ._. This_DT suggests_VBZ that_DT
          cyclin_NN D_NNP 
          1_CD is_VBZ promoting_VBG cell-cycle_JJ progression_NN
          during_IN the_DT proliferation_NN of_IN epithelium_NN in_IN diseased_JJ
          kidneys_NNS ._.
        
        
          Cyclin_NNP D_NNP 1_CD and_CC phospho-p_JJ Rb_NNP (_( Ser_NNP 780_CD )_) expression_NN in_IN
          vitro_NN
          HIV-_NNP 1_CD expression_NN in_IN cultured_JJ podocytes_NNS recapitulates_NNS
          the_DT phenotypic_JJ abnormalities_NNS induced_VBN by_IN HIV-_NNP 1_CD expression_NN
          in_IN infected_JJ podocytes_NNS 
          in_IN vivo_NN ,_, specifically_RB
          proliferation_NN ,_, loss_NN of_IN contact-mediated_JJ growth_NN control_NN ,_,
          and_CC dedifferentiation_NN [_NN 6_CD 7_CD 8_CD ]_NN ._. To_TO determine_VB if_IN these_DT
          phenotypes_NNS were_VBD marked_VBN by_IN enhanced_JJ cyclin_NN D_NNP 
          1_CD and_CC phospho-p_JJ Rb_NNP (_( Ser_NNP 780_CD )_) expression_NN ,_,
          we_PRP utilized_JJ the_DT podocyte_NN cell-culture_JJ protocol_NN developed_VBN
          by_IN Rieser_NNP et_CC al_NN ._. [_NN 27_CD 28_CD ]_NN to_TO study_VB both_DT sub-confluent_JJ
          podocyte_NN growth_NN and_CC podocyte_NN growth_NN during_IN the_DT formation_NN
          of_IN mature_VBP cell-cell_JJ contacts_NNS at_IN confluence_NN ._. In_IN this_DT
          protocol_NN ,_, normal_JJ podocytes_NNS are_VBP growth-arrested_JJ 4_CD -_: 5_CD days_NNS
          after_IN initial_JJ confluence_NN and_CC are_VBP fully_RB differentiated_JJ
          with_IN mature_VBP cell-cell_JJ contacts_NNS approximately_RB 10_CD days_NNS
          later_RB ._. Figure_NN 2_CD Ashows_NNP that_DT cyclin_NN D_NNP 
          1_CD message_NN levels_NNS are_VBP nearly_RB equivalent_NN
          between_IN mock_JJ (_( "_'' wild-type_JJ "_'' )_) -_: ,_, control_NN virus-_NN ,_, and_CC
          HIV-_NNP 1_CD -_: infected_JJ subconfluent_NN podocytes_NNS ,_, although_IN only_RB the_DT
          HIV-_NNP 1_CD -_: infected_JJ subconfluent_NN podocytes_NNS had_VBD elevated_VBD levels_NNS
          of_IN cyclin_NN D_NNP 
          1_CD protein_NN ._. In_IN contrast_NN ,_, cell-cell_JJ
          contact_NN in_IN wild-type_JJ and_CC control-infected_JJ ,_, but_CC not_RB
          HIV-_NNP 1_CD -_: infected_JJ podocytes_NNS ,_, caused_VBD a_DT severe_JJ down-regulation_JJ
          of_IN cyclin_NN D_NNP 
          1_CD transcript_NN and_CC protein_NN concomitant_NN
          with_IN the_DT up-regulation_JJ of_IN synaptopodin_NN ,_, a_DT podocyte_NN
          differentiation_NN marker_NN [_NN 7_CD 28_CD ]_NN ,_, by_IN the_DT end_NN of_IN the_DT
          14_CD -_: day_NN differentiation_NN period_NN ._. Although_IN HIV-_NNP 1_CD infected_JJ
          podocytes_NNS showed_VBD some_DT decrease_NN in_IN cyclin_NN D_NNP 
          1_CD message_NN by_IN the_DT end_NN of_IN the_DT
          differentiation_NN period_NN ,_, cyclin_NN D_NNP 
          1_CD protein_NN levels_NNS remained_VBD elevated_VBD ,_,
          suggesting_VBG activation_NN by_IN HIV-_NNP 1_CD of_IN mechanisms_NNS that_WDT
          stabilize_VBP cyclin_NN D_NNP 
          1_CD protein_NN levels_NNS ._. Moreover_RB ,_,
          HIV-_NNP 1_CD -_: infected_JJ podocytes_NNS ,_, but_CC not_RB control-infected_JJ
          podocytes_NNS ,_, had_VBD readily_RB detectable_JJ phospho-p_JJ Rb_NNP (_( Ser_NNP 780_CD )_) at_IN
          the_DT end_NN of_IN the_DT differentiation_NN period_NN ,_, suggesting_VBG that_IN
          the_DT stably_RB up-regulated_JJ cyclin_NN D_NNP 
          1_CD protein_NN remained_VBD active_JJ in_IN promoting_VBG
          cell-cycle_JJ progression_NN (_( Figure_NN 2_CD B_NNP )_) ._. The_DT ongoing_JJ
          proliferation_NN of_IN HIV-_NNP 1_CD -_: infected_JJ podocytes_NNS following_VBG
          cell-cell_JJ contact_NN led_VBN to_TO the_DT formation_NN of_IN multiple_JJ foci_NN
          (_( Figure_NN 2_CD C_NNP )_) with_IN intense_JJ ,_, heterogenous_JJ nuclear_JJ cyclin_NN D_NNP 
          1_CD immunofluorescence_NN consistent_JJ with_IN
          ongoing_JJ asynchronous_JJ proliferation_NN in_IN this_DT population_NN of_IN
          cells_NNS (_( Figure_NN 3_LS )_) ._. These_DT data_NNS indicate_VBP that_IN HIV-_NNP 1_CD
          expression_NN in_IN infected_JJ podocytes_NNS induces_VBZ cyclin_NN D_NNP 
          1_CD and_CC phospho-p_JJ Rb_NNP (_( Ser_NNP 780_CD )_) expression_NN ,_,
          hallmarks_NNS of_IN cyclin_NN D_NNP 
          1_CD -_: mediated_JJ G_NNP 
          1_CD →_NN S_NNP progression_NN ._. The_DT data_NNS ,_, however_RB ,_,
          do_VBP not_RB prove_VB that_DT cyclin_NN D_NNP 
          1_CD expression_NN alone_RB is_VBZ sufficient_JJ to_TO
          cause_VB cell-cycle_JJ progression_NN ._.
        
        
          Requirement_NNP of_IN HIV-_NNP 1_CD expression_NN for_IN induction_NN of_IN
          cyclin_NN D_NNP 1_CD
          We_PRP sought_VBD to_TO further_VB confirm_VB that_IN HIV-_NNP 1_CD expression_NN ,_,
          and_CC not_RB some_DT idiosyncratic_JJ effect_NN of_IN infection_NN ,_, was_VBD
          directly_RB inducing_VBG cyclin_NN D_NNP 
          1_CD expression_NN in_IN infected_JJ podocytes_NNS ._.
          First_LS ,_, we_PRP utilized_JJ the_DT small_JJ molecule_NN cyclin-dependent_JJ
          kinase_NN inhibitor_NN ,_, flavopiridol_NN ,_, which_WDT at_IN low_JJ
          concentrations_NNS (_( e_SYM ._. g_SYM ._. ,_, less_JJR than_IN 100_CD nM_NN )_) can_MD selectively_RB
          suppress_VB HIV-_NNP 1_CD transcript_NN elongation_NN without_IN altering_VBG
          cellular_JJ transcripts_NNS in_IN cell_NN types_NNS of_IN various_JJ lineages_NNS ,_,
          including_VBG podocytes_NNS [_NN 7_CD 29_CD 30_CD ]_NN ._. Cyclin_NNP D_NNP 
          1_CD transcript_NN levels_NNS were_VBD followed_VBN
          before_RB ,_, during_IN ,_, and_CC after_IN treatment_NN of_IN confluent_NN
          wild-type_JJ or_CC HIV-_NNP 1_CD infected_VBN podocytes_NNS with_IN 50_CD nM_NN
          flavopiridol_NN ,_, a_DT dose_NN that_IN suppresses_NNS HIV-_NNP 1_CD transcription_NN
          by_IN 70_CD %_NN [_NN 7_CD ]_NN ._. Analysis_NNP of_IN HIV-_NNP 1_CD ,_, cyclin_NN D_NNP 
          1_CD ,_, and_CC glyceraldehyde-_NN 3_CD -_: phosphate_NN
          dehydrogenase_NN (_( G_NNP 3_CD PDH_NNP )_) transcript_NN levels_NNS in_IN podocytes_NNS
          treated_VBN with_IN flavopiridol_NN for_IN 2_CD days_NNS ,_, followed_VBN by_IN drug_NN
          washout_NN for_IN 1_CD day_NN ,_, showed_VBD that_DT cyclin_NN D_NNP 
          1_CD expression_NN paralleled_JJ HIV-_NNP 1_CD
          expression_NN in_IN infected_JJ podocytes_NNS before_RB ,_, during_IN and_CC after_IN
          suppression_NN of_IN HIV-_NNP 1_CD genes_NNS (_( Figure_NN 4_LS )_) ._. Secondly_RB ,_, we_PRP
          utilized_JJ single_JJ gene_NN mutants_NNS of_IN HIV-_NNP 1_CD [_NN 8_CD ]_NN to_TO determine_VB
          which_WDT HIV-_NNP 1_CD gene_NN (_( s_VBZ )_) may_MD be_VB involved_VBN with_IN up-regulating_JJ
          cyclin_NN D_NNP 
          1_CD expression_NN ._. Analysis_NNP of_IN cyclin_NN D_NNP 
          1_CD transcript_NN levels_NNS in_IN podocytes_NNS
          infected_VBN with_IN HIV-_NNP 1_CD singly_RB mutated_VBN with_IN premature_JJ stop_NN
          codons_NNS in_IN the_DT genes_NNS encoding_VBG the_DT various_JJ structural_JJ and_CC
          regulatory_JJ proteins_NNS of_IN HIV-_NNP 1_CD (_( except_IN 
          tat_NN ,_, which_WDT is_VBZ present_JJ in_IN every_DT
          virus_NN )_) showed_VBD that_DT 
          nef_NN -_: deficient_NN virus_NN did_VBD not_RB
          significantly_RB up-regulate_JJ cyclin_NN D_NNP 
          1_CD expression_NN when_WRB compared_VBN to_TO the_DT
          other_JJ mutant_JJ viruses_NNS (_( Figure_NN 5_LS )_) ._. Taken_VBN together_RB ,_, these_DT
          data_NNS indicate_VBP that_DT induction_NN of_IN cyclin_NN D_NNP 
          1_CD expression_NN requires_VBZ HIV-_NNP 1_CD gene_NN
          expression_NN and_CC that_IN HIV-_NNP 1_CD 
          nef_NN is_VBZ important_JJ for_IN this_DT
          induction_NN ._.
        
      
      
        Discussion_NNP
        The_DT mechanisms_NNS whereby_WRB HIV-_NNP 1_CD subverts_VBZ cell-cycle_JJ
        controls_NNS in_IN infected_JJ renal_JJ epithelium_NN have_VBP been_VBN unclear_JJ ._.
        Here_RB ,_, we_PRP demonstrate_VBP that_IN podocytes_NNS expressing_VBG HIV-_NNP 1_CD genes_NNS
        display_VBP the_DT hallmarks_NNS of_IN cyclin_NN D_NNP 
        1_CD -_: dependent_JJ cell-cycle_JJ progression_NN ,_,
        specifically_RB ,_, that_DT cyclin_NN D_NNP 
        1_CD transcript_NN and_CC protein_NN expression_NN are_VBP
        markedly_RB up-regulated_JJ ,_, and_CC that_IN levels_NNS of_IN phospho-p_JJ Rb_NNP
        (_( Ser_NNP 780_CD )_) ,_, a_DT target_NN of_IN cyclin_NN D_NNP 
        1_CD /_NN CDK-_NNP 4_CD /_NN 6_CD but_CC not_RB cyclin_NN E_NNP /_NN CDK-_NNP 2_CD
        complexes_NNS [_NN 24_CD ]_NN ,_, are_VBP induced_VBN 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN ._. In_IN addition_NN ,_, preliminary_JJ
        micro-array_JJ gene_NN profiling_VBG of_IN HIV-_NNP 1_CD -_: infected_JJ tubular_JJ
        epithelium_NN showed_VBD that_DT cyclin_NN D_NNP 
        1_CD expression_NN is_VBZ up-regulated_JJ several_JJ
        fold_VB when_WRB compared_VBN to_TO uninfected_JJ tubular_JJ epithelium_NN
        (_( Michael_NNP Ross_NNP ,_, personal_JJ communication_NN )_) ._. This_DT suggests_VBZ that_IN
        the_DT HIV-_NNP 1_CD -_: induced_VBN proliferation_NN of_IN infected_JJ renal_JJ
        epithelium_NN may_MD be_VB caused_VBN by_IN a_DT cyclin_NN D_NNP 
        1_CD -_: dependent_JJ mechanism_NN ,_, unlike_IN other_JJ
        viruses_NNS that_WDT bypass_NN a_DT requirement_NN for_IN G_NNP 
        1_CD -_: phase_NN cyclins_NNS to_TO trigger_VB aberrant_NN
        cell-cycle_JJ progression_NN ._. Moreover_RB ,_, normal_JJ cellular_JJ controls_NNS
        on_IN cell-cycle_JJ progression_NN appears_VBZ to_TO be_VB dysregulated_JJ by_IN
        HIV-_NNP 1_CD expression_NN because_IN cell-cell_JJ contact_NN and_CC
        differentiation_NN ,_, events_NNS that_WDT normally_RB lead_VB to_TO the_DT
        down-regulation_JJ of_IN cyclin_NN D_NNP 
        1_CD expression_NN [_NN 25_CD ]_NN ,_, did_VBD not_RB
        significantly_RB alter_VB cyclin_NN D_NNP 
        1_CD protein_NN levels_NNS in_IN HIV-_NNP 1_CD infected_JJ
        podocytes_NNS ._. This_DT suggests_VBZ a_DT novel_NN stabilization_NN of_IN cyclin_NN D_NNP 
        1_CD protein_NN in_IN podocytes_NNS by_IN HIV-_NNP 1_CD ._. We_PRP are_VBP
        exploring_VBG whether_IN this_DT occurs_VBZ from_IN enhanced_JJ translation_NN of_IN
        cyclin_NN D_NNP 
        1_CD message_NN and_CC /_NN or_CC decreased_VBD degradation_NN
        of_IN cyclin_NN D_NNP 
        1_CD protein_NN and_CC whether_IN other_JJ D-_NNP type_NN
        cyclins_NNS may_MD be_VB involved_VBN in_IN phosphorylating_VBG pRb_NN in_IN
        HIVAN_NNP ._.
        Prior_RB studies_VBZ in_IN HIV-_NNP 1_CD transgenic_JJ animals_NNS support_VBP the_DT
        model_NN that_IN HIV-_NNP 1_CD gene_NN products_NNS interact_NN with_IN endogenous_JJ
        mitogenic_JJ pathways_NNS in_IN infected_JJ renal_JJ epithelium_NN ._. [_NN 11_CD 12_CD 13_CD
        14_CD ]_NN ._. Kidney_NNP transplants_NNS between_IN normal_JJ and_CC transgenic_JJ
        Tg_NNP 26_CD siblings_NNS suggested_VBD that_IN specific_JJ HIV-_NNP 1_CD proteins_NNS within_IN
        the_DT kidney_NN ,_, and_CC not_RB circulating_VBG factors_NNS ,_, transform_VB infected_JJ
        renal_JJ epithelium_NN [_NN 13_CD ]_NN ._. Indeed_RB ,_, HIV-_NNP 1_CD transgenic_JJ mice_NNS
        generated_VBN with_IN an_DT HIV-_NNP 1_CD proviral_NN construct_VB mutated_VBN in_IN the_DT
        Nef_NNP "_'' PXXP_NNP "_'' SH_NNP 3_CD -_: binding_JJ motif_NN for_IN Src-family_NNP kinases_NNS failed_VBD
        to_TO develop_VB nephropathy_NN [_NN 31_CD ]_NN ,_, and_CC a_DT recent_JJ 
        in_IN vitro_NN analysis_NN of_IN podocytes_NNS
        infected_VBN with_IN single_JJ gene_NN mutants_NNS of_IN HIV-_NNP 1_CD further_JJ suggest_VBP
        that_IN Nef_NNP plays_VBZ a_DT central_JJ role_NN in_IN causing_VBG the_DT proliferative_JJ
        phenotype_NN in_IN HIVAN_NNP [_NN 8_CD ]_NN ._. Utilizing_NNP these_DT same_JJ single_JJ gene_NN
        mutant_JJ viruses_NNS ,_, we_PRP showed_VBD here_RB that_IN Nef_NNP appears_VBZ to_TO be_VB play_VB
        a_DT role_NN in_IN the_DT up-regulation_JJ of_IN cyclin_NN D_NNP 
        1_CD by_IN HIV-_NNP 1_CD 
        in_IN vitro_NN ._. Importantly_NNP ,_, these_DT single_JJ
        gene_NN mutants_NNS do_VBP not_RB exclude_VB the_DT possibility_NN that_IN other_JJ
        HIV-_NNP 1_CD gene_NN (_( s_VBZ )_) may_MD cooperate_VB with_IN 
        nef_NN to_TO induce_VB cyclin_NN D_NNP 1_CD ,_, particularly_RB
        
        tat_NN ,_, which_WDT is_VBZ present_JJ in_IN every_DT
        virus_NN ._. Cumulatively_NNP ,_, however_RB ,_, these_DT observations_NNS do_VBP suggest_VBP
        a_DT mechanism_NN whereby_WRB HIV-_NNP 1_CD expression_NN in_IN renal_JJ epithelium_NN
        may_MD induce_VB cyclin_NN D_NNP 
        1_CD :_: activation_NN of_IN Src-family_NNP kinases_NNS by_IN
        Nef_NNP would_MD be_VB expected_VBN to_TO up-regulate_JJ cyclin_NN D_NNP 
        1_CD gene_NN expression_NN and_CC promote_VB the_DT
        synthesis_NN and_CC stabilization_NN of_IN cyclin_NN D_NNP 
        1_CD protein_NN via_IN Src-_NNP Ras-_NNP MAPK_NNP and_CC
        Src-_NNP PI_NNP 3_CD K-_NNP mTOR_NN signal_NN transduction_NN pathways_NNS ,_, respectively_RB [_NN
        32_CD 33_CD 34_CD ]_NN ._. Interestingly_RB ,_, our_PRP$ unpublished_JJ 
        in_IN vitro_NN observations_NNS and_CC published_VBN
        data_NNS showing_VBG marked_VBN expression_NN of_IN basic_JJ fibroblast_NN growth_NN
        factor_NN in_IN the_DT interstitium_NN of_IN HIVAN_NNP kidneys_NNS [_NN 35_CD ]_NN suggest_VBP
        that_IN soluble_JJ mitogens_NNS may_MD be_VB important_JJ cofactors_NNS with_IN HIV-_NNP 1_CD
        expression_NN to_TO induce_VB cyclin_NN D_NNP 
        1_CD ._. Thus_RB ,_, interrupting_VBG HIV-_NNP 1_CD gene_NN
        expression_NN should_MD down-regulate_JJ cyclin_NN D_NNP 
        1_CD and_CC correct_VB the_DT phenotypic_JJ
        abnormalities_NNS in_IN infected_JJ podocytes_NNS ._. In_IN support_NN of_IN this_DT
        notion_NN ,_, we_PRP show_VBP here_RB that_DT cyclin_NN D_NNP 
        1_CD expression_NN parallels_NNS HIV-_NNP 1_CD expression_NN
        before_RB ,_, during_IN ,_, and_CC after_IN suppression_NN of_IN HIV-_NNP 1_CD
        transcription_NN with_IN flavopiridol_NN ,_, and_CC recently_RB ,_, we_PRP showed_VBD
        that_IN longer_JJR periods_NNS of_IN treatment_NN with_IN flavopiridol_NN
        ameliorate_NN the_DT phenotypic_JJ abnormalities_NNS of_IN infected_JJ
        podocytes_NNS [_NN 7_CD ]_NN ._.
      
      
        Conclusions_NNP
        The_DT following_VBG results_NNS of_IN this_DT study_NN suggest_VBP that_IN HIV-_NNP 1_CD
        expression_NN leads_VBZ to_TO cyclin_NN D_NNP 
        1_CD -_: mediated_JJ G_NNP 
        1_CD →_NN S_NNP progression_NN in_IN infected_JJ podocytes_NNS :_:
        cyclin_NN D_NNP 
        1_CD transcript_NN and_CC protein_NN levels_NNS are_VBP
        markedly_RB up-regulated_JJ ,_, phospho-_NN Rb_NNP (_( Ser_NNP 780_CD )_) levels_NNS are_VBP
        increased_VBN ,_, cyclin_NN D_NNP 
        1_CD protein_NN and_CC phospho-_NN Rb_NNP (_( Ser_NNP 780_CD )_) levels_NNS
        do_VBP not_RB decrease_VB with_IN podocyte_NN cell-cell_JJ contact_NN and_CC
        differentiation_NN ,_, and_CC the_DT up-regulation_JJ of_IN cyclin_NN D_NNP 
        1_CD requires_VBZ the_DT expression_NN of_IN HIV-_NNP 1_CD
        genes_NNS ,_, particularly_RB HIV-_NNP 1_CD 
        nef_NN ._. In_IN sum_NN ,_, these_DT results_NNS suggest_VBP
        HIV-induced_NNP cell-cycle_JJ mechanisms_NNS may_MD contribute_VB to_TO
        aberrant_NN epithelial_NN proliferation_NN in_IN HIVAN_NNP ._.
      
      
        Methods_NNP
        
          Podocyte_NNP cell_NN culture_NN and_CC infection_NN
          Murine_NNP podocytes_NNS immortalized_JJ with_IN
          interferon-inducible_JJ temperature-sensitive_JJ SV-_NNP 40_CD T_NN
          antigen_NN (_( 
          ts_NNS -_: SV-_NNP 40_CD T_NN )_) were_VBD isolated_VBN and_CC
          infected_VBN with_IN replication_NN incompetent_JJ GFP-expressing_NNP
          HIV-_NNP 1_CD virus_NN ,_, replication_NN incompetent_JJ GFP-expressing_NNP
          single-gene_JJ mutants_NNS of_IN HIV-_NNP 1_CD ,_, or_CC replication_NN incompetent_JJ
          GFP-expressing_NNP control_NN lentivirus_JJ containing_VBG GFP_NNP but_CC no_DT
          HIV-_NNP 1_CD genes_NNS as_RB previously_RB described_VBD [_NN 7_CD 8_CD ]_NN ._. In_IN all_DT
          cases_NNS ,_, 70_CD %_NN to_TO 80_CD %_NN of_IN podocytes_NNS showed_VBD GFP_NNP expression_NN 4_CD
          days_NNS post_NN infection_NN (_( data_NNS not_RB shown_VBN )_) ._. Podocytes_NNP were_VBD used_VBN
          before_IN passage_NN twenty_CD and_CC maintained_VBN in_IN RPMI_NNP 1640_CD (_( Life_NNP
          Technologies_NNPS )_) supplemented_JJ with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN ,_, 1_CD ×_NN
          PenStrep_NNP (_( Life_NNP Technologies_NNPS )_) ,_, and_CC 20_CD U_NNP /_NN ml_NN recombinant_JJ
          interferon-gamma_JJ (_( Life_NNP Technologies_NNPS )_) at_IN 33_CD °_NN C_NNP ._. Unless_IN
          otherwise_RB indicated_VBD ,_, all_DT studies_NNS were_VBD conducted_VBN at_IN cell_NN
          confluency_NN and_CC 14_CD days_NNS after_IN inactivation_NN of_IN 
          ts_NNS -_: SV-_NNP 40_CD T_NN at_IN the_DT non-permissive_JJ
          temperature_NN (_( 37_CD °_NN C_NNP )_) when_WRB wild-type_JJ podocytes_NNS are_VBP fully_RB
          differentiated_JJ [_NN 27_CD 28_CD ]_NN ._.
        
        
          Immunohistochemistry_NNP
          Kidneys_NNP from_IN three_CD 40_CD day-old_JJ Tg_NNP 26_CD heterozygous_JJ
          transgenic_JJ siblings_NNS demonstrating_VBG 2_CD +_NN proteinuria_NN
          (_( Chemstrip_NNP 2_CD GP_NNP ,_, Roche_NNP )_) and_CC three_CD of_IN their_PRP$ non-transgenics_JJ
          littermates_NNS were_VBD collected_VBN in_IN accordance_NN with_IN Animal_NNP Use_NNP
          and_CC Care_NNP Committee_NNP guidelines_NNS ,_, fixed_VBN (_( 10_CD %_NN buffered_JJ
          formalin_NN )_) ,_, then_RB paraffin-embedded_JJ (_( Department_NNP of_IN
          Pathology_NNP ,_, Mount_NNP Sinai_NNP School_NNP of_IN Medicine_NNP )_) ._. Four_CD micron_NN
          full_JJ coronal_NN kidney_NN sections_NNS from_IN each_DT animal_NN were_VBD
          adhered_VBD to_TO lysine-coated_JJ slides_NNS and_CC used_VBN for_IN
          immunodetection_NN of_IN phospho-_NN Rb_NNP (_( Ser_NNP 780_CD )_) as_IN follows_VBZ :_:
          sections_NNS were_VBD deparaffinized_JJ and_CC hydrated_JJ by_IN placing_VBG in_IN
          xylene_NN for_IN 8_CD minutes_NNS ,_, followed_VBN by_IN 3_CD minutes_NNS each_DT of_IN 100_CD %_NN ,_,
          96_CD %_NN ,_, 80_CD %_NN ,_, 70_CD %_NN ,_, 50_CD %_NN ,_, 30_CD %_NN ethanol_NN ,_, ending_VBG with_IN 10_CD minutes_NNS
          in_IN water_NN ;_: sections_NNS then_RB underwent_VBD antigen_NN retrieval_NN
          (_( Glyca_NNP Reagent_NNP ,_, Biogenex_NNP )_) followed_VBN by_IN immunodetection_NN
          (_( Super_NNP Sensitive_NNP Detection_NNP Kit_NNP ,_, Biogenex_NNP )_) of_IN phospho-_NN Rb_NNP
          (_( Ser_NNP 780_CD )_) after_IN a_DT 12_CD hour_NN incubation_NN with_IN a_DT 1_CD :_: 1000_CD
          dilution_NN of_IN rabbit_NN anti-phospho-_JJ Rb_NNP (_( Ser_NNP 780_CD )_) antibody_NN
          (_( Cell_NNP Signaling_NNP )_) or_CC control_NN rabbit_NN anti-sera_JJ (_( Biogenex_NNP )_)
          at_IN 4_CD °_NN C_NNP ._.
        
        
          Immunofluorescence_NNP
          Following_VBG the_DT 14_CD day_NN podocyte_NN differentiation_NN protocol_NN
          on_IN coverslips_NNS to_TO establish_VB mature_VBP podocytes_NNS ,_, wild-type_JJ
          and_CC HIV-_NNP 1_CD infected_JJ podocytes_NNS underwent_VBD immunofluorescent_NN
          detection_NN of_IN cyclin_NN D_NNP 
          1_CD as_IN follows_VBZ :_: coverslips_NNS were_VBD washed_VBN
          three_CD times_NNS with_IN 1_CD ×_NN PBS_NNP ,_, fixed_VBN in_IN 60_CD %_NN acetone_NN /_NN 3_CD ._. 7_CD %_NN
          formaldehyde_NN at_IN -_: 20_CD °_NN C_NNP for_IN 20_CD minutes_NNS ,_, then_RB washed_VBN twice_RB
          with_IN 1_CD ×_NN PBS_NNP ;_: the_DT coverslips_NNS where_WRB then_RB incubated_JJ with_IN a_DT
          1_CD :_: 200_CD dilution_NN of_IN rabbit_NN anti-cyclin_JJ D_NNP 
          1_CD antibody_NN (_( Santa_NNP Cruz_NNP Biotechnology_NNP )_)
          or_CC control_NN rabbit_NN sera_NN (_( Biogenex_NNP )_) for_IN 2_CD hours_NNS at_IN room_NN
          temperature_NN followed_VBN by_IN three_CD washes_NNS with_IN 1_CD ×_NN PBS_NNP ;_: the_DT
          coverslips_NNS were_VBD then_RB incubated_JJ with_IN a_DT 1_CD :_: 250_CD dilution_NN of_IN
          rhodamine-labeled_JJ donkey-anti-rabbit_JJ anti-sera_JJ (_( Chemicon_NNP )_)
          for_IN 45_CD minutes_NNS to_TO detect_VB the_DT primary_JJ antibody_NN ;_: following_VBG
          three_CD final_JJ washes_NNS with_IN 1_CD ×_NN PBS_NNP ,_, the_DT coverslips_NNS were_VBD
          mounted_VBN on_IN glass_NN slides_NNS using_VBG ProLong_NNP Antifade_NNP (_( Molecular_NNP
          Probes_NNP )_) for_IN fluorescent_NN detection_NN of_IN GFP_NNP and_CC cyclin_NN D_NNP 
          1_CD on_IN an_DT Olympus_NNP IX_CD 70_CD microscope_NN at_IN 100_CD
          ×_NN magnification_NN ._.
        
        
          Podocyte_NNP cell-cell_JJ contact_NN
          Total_NNP RNA_NNP and_CC protein_NN were_VBD extracted_VBN from_IN wild-type_JJ ,_,
          control-infected_JJ ,_, and_CC HIV-_NNP 1_CD infected_JJ podocytes_NNS during_IN the_DT
          Reiser_NNP ,_, et_CC al_NN ._. protocol_NN to_TO study_VB subconfluent_NN podocyte_NN
          growth_NN and_CC podocyte_NN growth_NN during_IN establishment_NN of_IN mature_VBP
          cell-cell_JJ contacts_NNS between_IN differentiated_JJ podocytes_NNS [_NN 27_CD
          28_CD ]_NN ._. Briefly_NNP ,_, RNA_NNP and_CC protein_NN were_VBD extracted_VBN from_IN
          parallel_JJ plates_NNS of_IN podocytes_NNS using_VBG TRIZOL_NNP Reagent_NNP or_CC RIPA_NNP
          buffer_NN ,_, respectively_RB ,_, under_IN three_CD conditions_NNS :_: 1_LS )_) during_IN
          sub-confluent_JJ growth_NN at_IN 33_CD °_NN C_NNP ;_: 2_LS )_) immediately_RB upon_IN
          reaching_VBG confluency_NN (_( day_NN zero_CD )_) ;_: and_CC 3_LS )_) on_IN day_NN 14_CD after_IN
          switching_VBG confluent_NN cultures_NNS to_TO 37_CD °_NN C_NNP ._. At_IN the_DT end_NN of_IN the_DT
          differentiation_NN protocol_NN (_( day_NN 14_CD )_) ,_, additional_JJ plates_NNS were_VBD
          stained_JJ to_TO detect_VB foci_NN formation_NN as_IN follows_VBZ :_: cells_NNS were_VBD
          washed_VBN with_IN 1_CD ×_NN PBS_NNP ,_, fixed_VBN in_IN methanol_NN for_IN 1_CD minute_NN ,_,
          stained_JJ with_IN bromophenol_NN blue_JJ for_IN 1_CD minute_NN ,_, then_RB washed_VBN
          again_RB with_IN 1_CD ×_NN PBS_NNP ._. In_IN experiments_NNS utilizing_VBG the_DT single_JJ
          gene_NN mutant_JJ of_IN HIV-_NNP 1_CD ,_, total_JJ RNA_NNP was_VBD extract_VB from_IN infected_JJ
          podocytes_NNS 14_CD days_NNS after_IN switching_VBG confluent_NN cultures_NNS to_TO
          37_CD °_NN C_NNP ._. All_DT experiments_NNS were_VBD performed_VBN twice_RB ._.
        
        
          Flavopiridol_NNP treatment_NN
          After_IN the_DT 14_CD -_: day_NN podocyte_NN differentiation_NN protocol_NN
          described_VBD above_IN ,_, total_JJ RNA_NNP was_VBD extracted_VBN from_IN wild-type_JJ
          and_CC HIV-_NNP 1_CD -_: infected_JJ podocytes_NNS before_IN treatment_NN with_IN
          flavopiridol_NN (_( Developmental_NNP Therapeutics_NNP Program_NNP ,_,
          National_NNP Cancer_NNP Institute_NNP )_) (_( day_NN 14_CD )_) ,_, two_CD days_NNS after_IN
          suppression_NN of_IN HIV-_NNP 1_CD transcription_NN with_IN media_NNS containing_VBG
          50_CD nM_NN flavopiridol_NN (_( day_NN 16_CD )_) ,_, and_CC one_CD day_NN after_IN drug_NN
          washout_NN using_VBG media_NNS without_IN flavopiridol_NN (_( day_NN 17_CD )_) ._. The_DT
          experiment_NN was_VBD performed_VBN twice_RB ._.
        
        
          Cyclin_NNP D_NNP 1_CD transcript_NN and_CC protein_NN
          RNA_NNP and_CC protein_NN samples_NNS were_VBD analyzed_VBN as_IN follows_VBZ :_:
          Podocyte_NNP RNA_NNP (_( 10_CD μg_NN )_) was_VBD analyzed_VBN by_IN northern_JJ blot_NN using_VBG
          probes_NNS for_IN HIV-_NNP 1_CD 
          nef-_NN LTR_NNP [_NN 7_CD ]_NN ,_, mouse_NN cyclin_NN D_NNP 
          1_CD (_( cDNA_NN generated_VBN by_IN RT-PCR_NNP from_IN mouse_NN
          podocytes_NNS and_CC verified_VBN by_IN sequence_NN analysis_NN )_) ,_,
          synaptopodin_NN [_NN 7_CD ]_NN ,_, and_CC G_NNP 3_CD PDH_NNP ._. Following_VBG 7_CD ._. 5_CD %_NN SDS_NNP /_NN PAGE_NNP ,_,
          podocyte_NN protein_NN (_( 20_CD μg_NN )_) was_VBD analyzed_VBN by_IN western_JJ blot_NN for_IN
          cyclin_NN D_NNP 
          1_CD (_( ECL_NNP detection_NN of_IN a_DT 1_CD :_: 1000_CD dilution_NN
          of_IN rabbit_NN anti-cyclin_JJ D_NNP 
          1_CD antibody_NN ,_, Santa_NNP Cruz_NNP BioTechnology_NNP )_) ._.
          Protein_NNP (_( 250_CD μg_NN )_) from_IN the_DT control-infected_JJ or_CC
          HIV-_NNP 1_CD -_: infected_JJ podocytes_NNS on_IN day_NN 14_CD of_IN the_DT differentiation_NN
          protocol_NN was_VBD also_RB analyzed_VBN by_IN western_JJ blot_NN for_IN total_JJ pRb_NN
          (_( ECL_NNP detection_NN of_IN a_DT 1_CD :_: 1000_CD dilution_NN of_IN rabbit_NN anti-_NN Rb_NNP ,_,
          Santa_NNP Cruz_NNP Biotechnology_NNP )_) and_CC phospho-_NN Rb_NNP (_( Ser_NNP 780_CD )_) (_( ECL_NNP
          detection_NN of_IN a_DT 1_CD :_: 500_CD dilution_NN of_IN rabbit_NN anti-phospho-_JJ Rb_NNP
          (_( Ser_NNP 780_CD )_) antibody_NN binding_JJ ,_, Cell_NNP Signaling_NNP )_) ._. Protein_NNP
          concentrations_NNS were_VBD determined_VBN using_VBG the_DT Bio-_NNP Rad_NNP Protein_NNP
          Assay_NNP (_( Bio-_NNP Rad_NNP Laboratories_NNPS )_) ,_, and_CC blotting_VBG of_IN equivalent_NN
          amounts_NNS of_IN protein_NN was_VBD confirmed_VBN by_IN transient_JJ staining_VBG of_IN
          membranes_NNS with_IN Ponceau_NNP S_NNP solution_NN (_( 0_CD ._. 5_LS %_NN Ponceau_NNP S_NNP /_NN 1_CD %_NN
          acetic_JJ acid_NN )_) and_CC by_IN western_JJ blot_NN for_IN β-actin_JJ (_( Chemicon_NNP )_) ._.
          Signal_NNP intensity_NN was_VBD calculated_VBN using_VBG the_DT UN-SCAN-IT_NNP gel_NN
          v_NN 4_CD ._. 3_LS (_( Silk_NNP Scientific_NNP )_) ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        P_NN ._. J_NNP ._. N_NNP ._. conceived_VBD and_CC designed_VBD the_DT study_NN ;_: performed_VBD the_DT
        immunohistochemistry_NN ,_, immunofluorescence_NN ,_, and_CC western_JJ
        blotting_VBG ;_: and_CC drafted_VBD the_DT manuscript_NN ._. M_NNP ._. S_NNP ._. cultured_JJ the_DT
        podocytes_NNS and_CC performed_VBD the_DT northern_JJ blotting_VBG ._. M_NNP ._. H_NNP ._.
        designed_VBN and_CC prepared_VBD the_DT single_JJ gene_NN mutants_NNS of_IN HIV-_NNP 1_CD ._.
        I_PRP ._. H_NNP ._. G_NNP ._. mentored_JJ the_DT authors_NNS and_CC participated_VBD in_IN the_DT study_NN 's_POS
        design_NN and_CC coordination_NN ._.
      
    
  
